DaVita Inc. (NYSE:DVA) Stock Has Consensus Target Price of $235.86 According to Analysts

Posted by Brenda Bartman on Nov 7th, 2026

DaVita Inc. (NYSE:DVA – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the seven ratings firms that are covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $235.86.

A number of analysts have issued reports on the company. UBS Group lifted their price target on DaVita from $270.00 to $287.00 and gave the stock a “buy” rating in a report on Monday. Truist Financial decreased their target price on DaVita from $250.00 to $215.00 and set a “hold” rating for the company in a research note on Friday, August 7th. Oppenheimer set a $220.00 price target on DaVita in a report on Friday, August 7th. Raymond James Financial set a $220.00 price target on shares of DaVita in a research note on Friday, August 7th. Finally, TD Cowen raised their price objective on shares of DaVita from $220.00 to $228.00 and gave the stock a “buy” rating in a report on Monday, November 2nd.

Get Our Latest Stock Analysis on DVA

Hedge Funds Weigh In On DaVita

Several large investors have recently bought and sold shares of DVA. Berkshire Hathaway Inc purchased a new stake in shares of DaVita in the 2nd quarter valued at about $6,425,269,000. BlackRock Inc. purchased a new position in DaVita during the 2nd quarter worth $547,520,000. Dimensional Fund Advisors LP grew its position in DaVita by 5.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,145,436 shares of the company’s stock worth $176,037,000 after purchasing an additional 56,336 shares during the last quarter. Bank of America Corp DE acquired a new position in DaVita in the second quarter valued at $145,057,000. Finally, Bank of New York Mellon Corp increased its stake in DaVita by 81.2% in the first quarter. Bank of New York Mellon Corp now owns 457,493 shares of the company’s stock valued at $70,312,000 after purchasing an additional 204,984 shares during the period. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Trading Down 1.8%

DVA traded down $3.55 on Friday, hitting $191.27. 603,670 shares of the company were exchanged, compared to its average volume of 796,165. The firm has a 50-day moving average price of $182.52 and a two-hundred day moving average price of $178.61. DaVita has a twelve month low of $101.00 and a twelve month high of $247.49. The company has a market cap of $12.03 billion, a price-to-earnings ratio of 14.08, a price-to-earnings-growth ratio of 0.47 and a beta of 0.87.

DaVita (NYSE:DVA – Get Free Report) last released its earnings results on Thursday, October 29th. The company reported $3.82 earnings per share for the quarter, topping analysts’ consensus estimates of $3.57 by $0.25. DaVita had a net margin of 6.49% and a negative return on equity of 225.93%. The firm had revenue of $3.58 billion for the quarter, compared to analyst estimates of $3.52 billion. During the same period in the prior year, the firm earned $2.51 earnings per share. The business’s quarterly revenue was up 4.6% compared to the same quarter last year. Equities analysts expect that DaVita will post 14.66 EPS for the current year.

DaVita Company Profile

(Get Free Report)

DaVita Inc (NYSE: DVA) is a health care services company focused on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis treatments for people with chronic kidney failure, including in-center hemodialysis, home dialysis and related clinical support services.

DaVita also offers integrated kidney care programs intended to support patients across the stages of chronic kidney disease. Its services may include care coordination, disease management, education, transplant support and other services designed to improve clinical outcomes and help manage the needs of patients with complex kidney conditions.

The company operates a network of dialysis centers and related facilities in the United States and serves patients in select international markets.